Lexicon Pharma (LXRX) Tops Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.17 +0.93%
EPS Growth %: -600.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -600.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $1.65 million versus the consensus estimate of $3.44 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump on Iran: we're trying to work out a deal that's fair
- Wealthfront launches custodial account with tax-gain harvesting
- Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
